肿瘤坏死因子α抑制剂诱导的银屑病研究进展

doi:10.35541/cjd.20200251

Abstract

Abstract: 【Abstract】 Tumor necrosis factor-α （TNF-α） inhibitors have been widely used and proven to be effective in the treatment of various inflammatory disorders in recent years, but there is a noteworthy and paradoxical adverse drug reaction that cannot be ignored, that is, TNF-α inhibitor-induced psoriasis. Its pathological manifestations could be psoriasiform or spongiotic changes, and its pathogenesis may be related to the imbalance between TNF-α and type Ⅰinterferon, the involvement of interleukin-23/T helper 17 axis, or infection. This review elaborates the epidemiological, histopathological features and possible pathogenesis of TNF-α inhibitor-induced psoriasis, and provides a basis for recognition and treatment of TNF-α inhibitor-induced psoriasis.

Key words: Psoriasis, Tumor necrosis factor-alpha, Biological agents, Adverse reactions, Tumor necrosis factor-α inhibitor-induced psoriasis

Sun Jie, Wang Rui, Li Chengxin. Tumor necrosis factor-α inhibitor?induced psoriasis[J]. Chinese Journal of Dermatology, 2022, 55(9): 821-824.doi:10.35541/cjd.20200251

References ［38］

［1］	Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti⁃tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study［J］. Ann Intern Med, 2016,164（1）:10⁃22. doi: 10.7326/M15⁃0729.
［2］	Li SJ, Perez⁃Chada LM, Merola JF. TNF inhibitor⁃induced psoriasis: proposed algorithm for treatment and management［J］. J Psoriasis Psoriatic Arthritis, 2019,4（2）:70⁃80. doi: 10.1177/2475530318810851.
［3］	Mazloom SE, Yan D, Hu JZ, et al. TNF⁃α inhibitor⁃induced psoriasis: a decade of experience at the cleveland clinic［J］. J Am Acad Dermatol, 2020,83（6）:1590⁃1598. doi: 10.1016/j.jaad. 2018.12.018.
［4］	Montolio Chiva L, Martínez FÀ, Mateu Puchades A, et al. Psoriasis induced by biological therapy［J］. Reumatol Clin, 2020,4:S1699⁃258X（20）30019⁃X. doi: 10.1016/j.reuma.2019. 12.005.
［5］	Benzaquen M, Flachaire B, Rouby F, et al. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn′s disease⁃associated spondyloarthropathy［J］. Rheumatol Int, 2018,38（7）:1297⁃1299. doi: 10.1007/s00296⁃018⁃4034⁃0.
［6］	Verea MM, Del Pozo J, Yebra⁃Pimentel MT, et al. Psoriasiform eruption induced by infliximab［J］. Ann Pharmacother, 2004,38（1）:54⁃57. doi: 10.1345/aph.1C477.
［7］	Brown G, Wang E, Leon A, et al. Tumor necrosis factor⁃α inhibitor⁃induced psoriasis: systematic review of clinical features, histopathological findings, and management experience［J］. J Am Acad Dermatol, 2017,76（2）:334⁃341. doi: 10.1016/j.jaad.2016.08.012.
［8］	单芳芳. TNF⁃α拮抗剂诱发或加重银屑病的临床特征与处理［D］. 苏州: 苏州大学, 2019. doi：10.27351/d.cnki.gszhu.2019. 001331.
［9］	李高洁, Krista Shrestha, 马文婷, 等. 阿达木单抗诱发银屑病样皮炎1例［J］. 中国皮肤性病学杂志, 2019,33（12）:1416⁃1418. doi: 10.13735/j.cjdv.1001⁃7089.201901121.
［10］	Guerra I, Pérez⁃Jeldres T, Iborra M, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti⁃TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study［J］. Inflamm Bowel Dis, 2016,22（4）:894⁃901. doi: 10.1097/MIB.0000000000000757.
［11］	Guerra I, Algaba A, Pérez⁃Calle JL, et al. Induction of psoriasis with anti⁃TNF agents in patients with inflammatory bowel disease: a report of 21 cases［J］. J Crohns Colitis, 2012,6（5）:518⁃523. doi: 10.1016/j.crohns.2011.10.007.
［12］	Groth D, Perez M, Treat JR, et al. Tumor necrosis factor⁃α inhibitor⁃induced psoriasis in juvenile idiopathic arthritis patients［J］. Pediatr Dermatol, 2019,36（5）:613⁃617. doi: 10.1111/pde.13859.
［13］	Courbette O, Aupiais C, Viala J, et al. Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease［J］. J Pediatr Gastroenterol Nutr, 2019,69（2）:189⁃193. doi: 10.1097/MPG.0000000000002349.
［14］	Sondermann W, Herz S, Sody E, et al. Dermatological complications of therapy with biologics in inflammatory autoimmune diseases［J］. J Dtsch Dermatol Ges, 2019,17（10）:1029⁃1037. doi: 10.1111/ddg.13964.
［15］	Harrison MJ, Dixon WG, Watson KD, et al. Rates of new⁃onset psoriasis in patients with rheumatoid arthritis receiving anti⁃tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register［J］. Ann Rheum Dis, 2009,68（2）:209⁃215. doi: 10.1136/ard.2007.087288.
［16］	Hernández MV, Sanmartí R, Cañete JD, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases［J］. Arthritis Care Res （Hoboken）, 2013, 65（12）: 2024⁃2031. doi: 10.1002/acr.22096.
［17］	Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti⁃tumor necrosis factor therapy: a paradoxical adverse reaction［J］. Arthritis Rheum, 2005,52（8）:2513⁃2518. doi: 10. 1002/art.21233.
［18］	Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis［J］. Semin Arthritis Rheum, 2010,40（3）:233⁃240. doi: 10.1016/j.semarthrit.2010.04.003.
［19］	Dalkilic E, Bulbul Baskan E, Alkis N, et al. Tumor necrosis factor⁃alpha antagonist therapy⁃induced psoriasis in Turkey: analysis of 514 patients［J］. Mod Rheumatol, 2012,22（5）:738⁃742. doi: 10.1007/s10165⁃011⁃0590⁃9.
［20］	孙婧, 张建中. 阿达木单抗治疗类风湿关节炎引起银屑病一例［J］. 中华皮肤科杂志, 2018,51（10）:760. doi: 10.3760/cma.j.issn.0412⁃4030.2018.10.015.
［21］	Aslanidis S, Pyrpasopoulou A, Douma S, et al. Tumor necrosis factor⁃a antagonist⁃induced psoriasis: yet another paradox in medicine［J］. Clin Rheumatol, 2008,27（3）:377⁃380. doi: 10. 1007/s10067⁃007⁃0789⁃5.
［22］	Eickstaedt JB, Killpack L, Tung J, et al. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti⁃tumor necrosis factor alpha agents［J］. Pediatr Dermatol, 2017,34（3）:253⁃260. doi: 10.1111/pde. 13081.
［23］	Napolitano M, Balato N, Caso F, et al. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study［J］. Clin Exp Rheumatol, 2017,35（1）:137⁃140.
［24］	Havmose M, Thomsen SF. Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases［J］. Int J Dermatol, 2017,56（11）:1087⁃1102. doi: 10.1111/ijd.13691.
［25］	Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF⁃blockade therapy: a review and analysis of 127 cases［J］. J Dermatolog Treat, 2009,20（2）:100⁃108. doi: 10.1080/09546630802441234.
［26］	郭金竹, 王文慧, 叶珍珍, 等. 英夫利昔单抗治疗30例银屑病患者的疗效与安全性［J］. 中国皮肤性病学杂志, 2019,33（3）:265⁃269. doi: 10.13735/j.cjdv.1001⁃7089.201804074.
［27］	Murphy MJ, Cohen JM, Vesely MD, et al. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis［J/OL］. J Am Acad Dermatol, 2020,8:S0190⁃9622（20）33154⁃6［2021⁃01⁃28］. https://sci⁃hub.ren/10.1016/j.jaad.2020. 12.010. doi: 10.1016/j.jaad.2020. 12.010.
［28］	Hu JZ, Billings SD, Yan D, et al. Histologic comparison of tumor necrosis factor⁃α inhibitor⁃induced psoriasis and psoriasis vulgaris［J］. J Am Acad Dermatol, 2020,83（1）:71⁃77. doi: 10. 1016/j.jaad.2020.01.006.
［29］	Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis［J］. Clin Dermatol, 1998,16（3）:333⁃351. doi: 10.1016/s0738⁃081x（98）00005⁃4.
［30］	Hawryluk EB, Linskey KR, Duncan LM, et al. Broad range of adverse cutaneous eruptions in patients on TNF⁃alpha antagonists［J］. J Cutan Pathol, 2012,39（5）:481⁃492. doi: 10.1111/j.1600⁃0560.2012.01894.x.
［31］	Skrzeczynska⁃Moncznik J, Zabieglo K, Bossowski JP, et al. Eosinophils regulate interferon alpha production in plasmacytoid dendritic cells stimulated with components of neutrophil extracellular traps［J］. J Interferon Cytokine Res, 2017,37（3）:119⁃128. doi: 10.1089/jir.2016.0036.
［32］	Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis［J］. Nat Commun, 2018,9（1）:25. doi: 10.1038/s41467⁃017⁃02466⁃4.
［33］	Garcovich S, De Simone C, Genovese G, et al. Paradoxical skin reactions to biologics in patients with rheumatologic disorders［J］. Front Pharmacol, 2019,10:282. doi: 10.3389/fphar.2019.00 282.
［34］	Jean LB, Joseph LJ, Ronald PR, et al. Dermatology（皮肤病学）［M］. 朱学骏, 王宝玺, 孙建方, 等, 译. 北京: 北京大学医学出版社, 2014: 155.
［35］	Fania L, Morelli M, Scarponi C, et al. Paradoxical psoriasis induced by TNF⁃α blockade shows immunological features typical of the early phase of psoriasis development［J］. J Pathol Clin Res, 2020,6（1）:55⁃68. doi: 10.1002/cjp2.147.
［36］	Mylonas A, Conrad C. Psoriasis: classical vs. paradoxical. The Yin⁃Yang of TNF and type i interferon［J］. Front Immunol, 2018,9:2746. doi: 10.3389/fimmu.2018.02746.
［37］	Bucalo A, Rega F, Zangrilli A, et al. Paradoxical psoriasis induced by anti⁃TNFα treatment: evaluation of disease⁃specific clinical and genetic markers［J/OL］. Int J Mol Sci, 2020,21（21）:7873［2020⁃01⁃28］. https://sci⁃hub.st/10.3390/ijms21217873. doi: 10.3390/ijms21217873.
［38］	Özkur E, Altunay İK, Leblebici C, et al. Adalimumab⁃induced scalp psoriasis with severe alopecia［J］. Dermatol Ther, 2019,32（5）:e13033. doi: 10.1111/dth.13033.

[1]	Zhou Xue, Yu Zengyang, Chen Youdong, Guo Chunyuan, Yu Qian, Hu Yifan, Yao Lingling, Shi Yuling, . Tumor necrosis factor α-mediated low expression of fatty acid desaturase 2 in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 752-758.
[2]	Yao Lingling, Yu Zengyang, Guo Chunyuan, Zhou Jing, Cui Lian, Yu Qian, Yu Yingyuan, Zhou Xue, Cai Jiangluyi, Shi Yuling, . Changes in circadian gene cryptochrome 2 expression in mouse models of psoriasis and HaCaT cells and their underlying mechanisms [J]. Chinese Journal of Dermatology, 2022, 55(9): 759-766.
[3]	Yu Chen, Wang Gang. Small-molecule targeted agents: new choices for the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 747-751.
[4]	Liu Jin, Shen Zhengyu. Epigenetic regulation in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 825-829.
[5]	Xiao Chunying, Wang Gang. Roles of Langerhans cells in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 830-834.
[6]	Zheng Jiayuan, Yu Bingqian, Chen Xianxia, Luo Zhicheng. Characteristics of pruritus in adult patients with psoriasis vulgaris and its effect on quality of life [J]. Chinese Journal of Dermatology, 2022, 55(9): 790-794.
[7]	Jin Liang, Liu Ling. Treatment of some genodermatoses [J]. Chinese Journal of Dermatology, 2022, 55(8): 735-739.
[8]	Gao Zirui, Zhao Pei, Dou Yuanqing, Liu Ping, Zhang Jianzhong. Efficacy and safety of dupilumab in the treatment of adult prurigo nodularis [J]. Chinese Journal of Dermatology, 2022, 55(7): 562-565.
[9]	Wang Lingyan, Pan Jing, Miao Gang, Chang Xiaodan, Jin Qiuzi, Guo Ningning, Zhang Jiayu. Analysis of difficult-to-treat sites in patients with psoriasis who received biological therapy [J]. Chinese Journal of Dermatology, 2022, 55(7): 583-587.
[10]	Working Group for Atopic Dermatitis, Chinese Society of Dermatology, Working Group for Children′s Diseases, Chinese Society of Dermatology. Treatment of atopic dermatitis with dupilumab: an expert consensus [J]. Chinese Journal of Dermatology, 2022, 55(6): 465-470.
[11]	Committee on Autoimmune Diseases, China Dermatologist Association. Cyclosporine in the treatment of immune-related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2022, 55(6): 471-479.
[12]	Zhao Liuqi, Chen Yan, Chen Danyang, Fan Birao, Wang Rui, Shang Panpan, Chen Xixue, Zhu Xuejun, Wang Mingyue. Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study [J]. Chinese Journal of Dermatology, 2022, 55(6): 480-485.
[13]	Huang Xin, Chen Xiaoyun, Li Yaping, Liang Xingkun, Zhang Guiying, Zhou Ying, Zhan Yi, Luo Shuaihantian, Liao Jieyue, Xiao Rong, Long Hai. Efficacy and safety of dupilumab in the treatment of 123 cases of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(6): 486-493.
[14]	Shan Ying, Zuo Yagang. Correlation between autoimmune bullous diseases and psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(5): 452-455.
[15]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2021 [J]. Chinese Journal of Dermatology, 2022, 55(4): 369-372.

Tumor necrosis factor-α inhibitor?induced psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［38］

Related Articles 15

Metrics

Comments

Recommended 10